Global Mesalazine Market Research Report 2020

Mesalazine, also known as mesalamine or 5-aminosalicylic acid (5-ASA), is a medication used to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease. It is generally used for mildly to moderately severe disease. It is taken by mouth or rectally. The formulations which are taken by mouth appear to be similarly effective.
In 2018, the global Mesalazine market is lead by Europe. India is the second-largest region-wise market.
As for the consumption, Europe is the largest consumer, who owned 43.76% share in global consumption market in 2018, consumption volume was 1240.5 MT. The follower is India, with the consumption volume of 519.0 K MT in 2018, accounting for 18.31% sales share in 2018.

Syntese A/S was the largest manufacturer in 2018, with a market share of 23%. Other top 5 manufacturers were Divis Laboratories, Cambrex Corporation, Ipca Laboratories and PharmaZell, with total market share of 52%.

The global Mesalazine market is valued at 130.3 million US$ in 2020 is expected to reach 174.3 million US$ by the end of 2026, growing at a CAGR of 4.2% during 2021-2026.
This report focuses on Mesalazine volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Mesalazine market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and India etc.
Market Segment Analysis
The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type, the Mesalazine market is segmented into
Purity ≥ 97 %
Purity ≥ 98 %
Purity ≥ 99 %
Purity≥98% occupied the largest sales share of 60.32% in 2018, consumption volume was 1346.6 MT. Purity≥99% growth fastest in the forecast period with a CAGR of 4.46% from 2019 to 2025.

Segment by Application
Mesalazine Tablets
Mesalazine Capsules
Others
In 2018, the consumption volume of Mesalazine Tablets was 1456.0 MT, accounting for 51.36% of global share. And it excepted to reach 1811.9 MT in 2025, with the CAGR of 3.41% from 2019 to 2025, slightly lower than global market growth.

Global Mesalazine Market: Regional Analysis
The Mesalazine market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.
The key regions covered in the Mesalazine market report are:
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Global Mesalazine Market: Competitive Analysis
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.
The major players in global Mesalazine market include:
Syntese A/S
Divis Laboratories
Cambrex Corporation
Ipca Laboratories
PharmaZell
Lasa Loboratory
Erregierre SpA
Corden Pharma Bergamo
CTX Lifescience
Ishita Active Pharma Ingredients
YC Biotech (Jiangsu)
Xinxiang Tianfeng Fine Chemical

Frequently Asked Questions